Novo Nordisk A/S (NVO)

47.77 -1.19 (-2.43%) USD  |  NYSE  |  Dec 17, 16:00
48.00 +0.23 (+0.48%) Pre-Market: 04:44
More

Novo Nordisk Research and Development Expense (Annual): 5.514B for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for NVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Evaxion AS 10.14M
Ascendis Pharma A/S 324.02M
Regeneron Pharmaceuticals, Inc. 4.624B
Omeros Corp. 119.52M
Viking Therapeutics, Inc. 101.64M